CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR Therapeutics (CRSP) reported earnings of $1.10 per share for the fourth quarter of 2023 against the Zacks Consensus Estimate of a loss of 40 cents. In the year-ago period, the company had incurred a loss of$1.41 per share.The positive result was driven by collaboration revenue received from Vertex (VRTX) in connection with the approval of Casgevy (exagamglogene autotemcel [exa-cel]) for two blood disorder indications. Shares of CRSP rose 4.7% on Feb 21 as investors cheered the encouraging financial ...